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1. Introduction
Sarcoidosis is a systemic inflammatory disease of unknown etiology. The hallmark histological
feature of the disease is epithelioid cell granuloma derived from activated T cells and macro‐
phages triggered by unknown immune stimuli such as bacterial protein or beryllium metal [1,
2]. Various inflammatory cytokines and growth factors can participate in the pathophysiolog‐
ical processes of sarcoidosis [1].
Sarcoidosis is fundamentally a chronic inflammatory disease. The pathological and clinical
courses vary widely from spontaneous regression to fibrotic progression leading to various
patterns of organ dysfunction [3].
Any of the following may be selected as therapeutic targets for sarcoidosis, depending on the
pathophysiology and evolution of the disease: 1) delete the etiological agents, 2) attenuate the
hyperimmune reactions directly underlying the epithelioid cell granuloma formation, 3) arrest
any pathophysiological processes that tend to persist, 4) relieve functional disturbances caused
by fibrotic lesions, 5) replace disabled organs by transplantation.
It is critical to grasp or predict the whole clinical course of sarcoidosis when considering
therapies.
Corticosteroids, the established standard therapy for sarcoidosis, have drawbacks. While
corticosteroids are reliably therapeutic, some patients manifest adverse effects during treat‐
ment or functional declines in spite of treatment [4]. Corticosteroids may also disturb the
defensive function of granulomas surrounding etiological antigens or disturb healing proc‐
esses by attenuating various inflammatory processes homogeneously.
© 2013 Nagai and Izumi; licensee InTech. This is an open access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
In this article we review the widely variable clinical courses sarcoidosis is known to take. We
also try to propose a therapeutic strategy for stably managing chronic sarcoidosis, especially
for patients with involvement of vital organs such as the lung and heart.
2. Therapeutic problems and clinical courses
The clinical courses of sarcoidosis vary considerably. The disease spontaneously regresses in
about 10-20 % of patients, persists in chronic form in another 30-50 %, relapses and recurs in
another 20-30 %, and deteriorates in about 10 % [3].
The clinical phenotypes associated with the various clinical courses have been proposed based
on a review of 400 sarcoidosis cases collected all over the world. The WASOG Task Force
classified 9 phenotypes according to evaluations of clinical courses up to 5 years after detection
(see Fig. 1) [5]. Among cases in Japan, sarcoidosis is presumed to reach the chronic stage when
chest radiographic abnormalities persist for five years after detection [3]. According to the
clinical phenotypes classified by WASOG, 17 % of cases spontaneously regress, 8 % deteriorate,
34 % manifest minimal remaining lesions with or without therapies, and 34 % progress to the
chronic stage with or without treatment [5]. Among the patients who receive treatment, 40 %
reportedly relapse after the corticosteroids are tapered or discontinued altogether [6]. The
ACCESS study reported multiple lesion sites, lesion frequency by site, and various associations
of clinical characteristics with the patient age, sex, number of lesions, and population differ‐
ences [7]. Though the frequencies vary, functional deterioration has been reported in all
affected organs. The clinical course of sarcoidosis is stable in 80 % of cases at 2 years after
detection, though the prognosis tends to be worse in African Americans [8].
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Figure 1. Clinical phenotypes of sarcoidosis patients proposed by WASOG 2005. Minimal disease is defined as less
than 25 % of maximal lesions
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3. Sarcoidosis therapy
Therapy is indicated for sarcoidosis patients with lesions of the heart, with pulmonary fibrosis
in bronchovascular bundle areas, with neurosarcoidosis, and with systemic symptoms such
as fever, malaise, and ocular lesions. The therapies administered tend to be prolonged in most
patients with chronic lesions.
According to a meta-analysis by Reich, excessive corticosteroid therapy may unfavorably
influence the long-term course of the disease in some individuals [9]. Among 948 sarcoidosis
patients retrospectively reviewed by our group, 28 had advanced pulmonary sarcoidosis, 13
of those 28 advanced cases died, and 9 of those deceased cases had received corticosteroids [3].
Another retrospective study from Japan reported corticosteroid response in 70-80 % of 195
sarcoidosis patients, although the rate was lower, that is, only 48 %, in patients with cardiac
sarcoidosis [4].
Methotrexate, one of the alternative drug treatments for sarcoidosis, is prescribed mainly for
chronic sarcoidosis and can be expected to confer a steroid-sparing effect in addition to an
immunomodulatory effect [10]. Methotrexate is reported to be therapeutically effective mainly
in cases with skin lesions [11], ocular lesions [12], neuromuscular lesions [13],etc. In our clinical
experience the agent is therapeutically effective, albeit incompletely, for sarcoidosis involving
lesions of the lung, heart, and neuromuscular system. Long-term therapy is mandatory for
chronic sarcoidosis, especially for the prevention of functional declines that can lead to
congestive cardiac failure or sudden death in cases with cardiac lesions. Corticosteroid therapy
may fail to prevent functional deteriorations longitudinally [12]. The Delphi study offered no
precise guidance on how to treat sarcoidosis with corticosteroids or alternative agents [14,15].
In this chapter we try to introduce our own clinical experience with pulmonary and cardiac
sarcoidosis.
3.1. Treatment for pulmonary sarcoidosis
Patients with sarcoidosis present with various types of pulmonary lesions, some of which
spontaneously regress and some of which show fibrotic deterioration [16,17]. Fibrotic lesions
situated along the bronchovascular bundle of the lung are likely to result in chronic airflow
limitations [18] and bronchial distortions of a type often associated with infections such as
nontuberculous mycobacterium, pseudomonas aeruginosa, and aspergillus fumigatus [16,19].
Some patients with pulmonary fibrosis also develop pulmonary hypertension [20]. Lung
transplantation is considered when the disease progresses to a severe stage in patients under
60 years old [21,22].
Therapy itself might cause opportunistic infection under these circumstances. No medicines
available at present are definitively effective at attenuating the fibrotic progression along the
bronchovascular bundles. It usually takes 5-10 years before the fibrotic progression leads to
chronic respiratory failure [3]. Longitudinal management and treatment must continue for
long durations without adverse effects, as chronic respiratory failure persists for several years
after it first manifests [3]. From this standpoint, methotrexate may be an available option for
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pulmonary sarcoidosis. Unlike methotrexate therapy for rheumatoid arthritis, methotrexate
for sarcoidosis has seldom led to drug-related pneumonia in our clinical experience.
Presentation of two cases
Case 1: 59-year-old male, never-smoker, no occupational exposure
Patient 1 visited our institution, Central Clinic, with complaints of a severe cough and
exertional dyspnea. His chest radiograph showed diffuse pulmonary lesions with fibrosis
mainly distributed on the upper and middle lung fields (Figure 2 ). Transbronchial lung biopsy
revealed epithelioid cell granuloma. Having found no obvious infection at the initial exami‐
nation, we started the patient on prednisolone (10 mg /day) and methotrexate (6 mg/week).
After therapy his symptoms gradually attenuated. The opacities decreased during treatment
in radiological images, but not drastically on CT findings (Figure 3). Pulmonary function
results showed improved diffusion capacity and the patient reported an abatement of his
cough and exertional dyspnea. The airflow limitation, however, gradually worsened (Table 1). 
 
 
％FVC (%) 
FEV1 (l) 
FEV1% (%) 
%DLCO (%) 
 
EF 
Reg.   
sPAP mmHg 
ACE 
1,25-(OH)2VD 
3 years  
 
58.2  
1.56 l 
79.6 
61.5 
 
53.9 
I 
31.8 
14.3 
5 years 
 
55.0 
1.48 l 
76.2 
61.4 
 
57.4 
I 
42.4  
15.3 
Initial exam. 
 
55.6 
1.88 l 
89.9 
51.3 
 
67.6 
I 
32.9 
14.1 
75.3 
FVC: forced vital capacity, FEV1: forced expiratory vital capacity one second,
DLCO: diffusion lung capacity carbon monoxide
EF: ejection fraction, Reg. : regurgitation, sPAP : systolic pulmonary artery pressure
ACE: angiotensin converting enzyme, 1,25-(OH)2 VD: 1,25-OH)2 vitamine D
Table 1. Change in the functional or blood markers over time: 59 M Ns
No pulmonary hypertension appeared in a cardiac echogram. No blood markers suggestive
of disease activity (serum ACE, 1,25-(OH)2 vitamin D) appeared in association with the
treatment course (Table 1). The patient’s symptoms almost wholly abated and his prednisolone
and methotrexate were tapered to 3 mg/day and 2 mg/week, respectively. No adverse effects
were found during treatment.
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Figure 2. Longitudinal course of pulmonary fibrosis in patients with sarcoidosis: Plain chest radiograph 59-year-old
male, nonsmoker, chief complaints of cough and exertional dyspnea a : when corticosteroids and methotrexate were
introduced b: after 3 years of treatment c: after 5 years of treatment
2/7/04
7/10/07
8/22/09
a
b
c
Figure 3. Longitudinal course of pulmonary fibrosis in patients with sarcoidosis: High-resolution CT findings a : when
corticosteroids and methotrexate were introduced b: after 3 years of treatment c: after 5 years of treatment
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Case 2. 60-year-old male, ex-smoker, no occupational exposure
Ocular lesions and BHL were detected by a health survey 27 years earlier, in 1982. A trans‐
bronchial lung biopsy at the time revealed epithelioid cell granuloma, and few parenchymal
lesions of the lung were evident on HRCT. After an initial examination at Kyoto University,
the patient moved away from Kyoto for his work. In the intervening 27 years we had no
opportunity to follow his condition. In 2008, the patient visited our clinic because of exertional
dyspnea and a severe cough with sputum production. Bilateral fibrotic lung lesions had
developed on his upper lungs (Figure 4). Having detected no obvious infection, we started the
patient on prednisolone (5 mg/day) and methotrexate (6 mg/week). His symptoms improved
considerably by the end of the third month after treatment and he remained stable thereafter.
Pulmonary function results also demonstrated a mild increase in %DLCO 18 months after the
treatment commenced (Table 2). Ｙ．Ｎ   
%FVC (%) 
FEV1 (l) 
FEV1% (%) 
%DLCO (%) 
 
DOE 
cough 
27 yrs before 
68.2 
2.02 
86.3 
ND 
 
Grade 3 
severe 
PSL+MTX 
61.3 
1.85 
86.0 
39.6 
 
Grade 3 
severe 
3 mos 
66.1 
2.04 
ND 
39.3 
 
Grade 2 
moderate 
12 mos 
70.4 
2.08 
84.2 
41.0 
 
Grade 2 
mild 
18 mos 
69.1 
1.92 
79.7 
49.0 
 
Grade 1 
mild 
FVC: forced vital capacity, FEV1: forced expiratory vital capacity one second,
DLCO: diffusion lung capacity carbon monoxide
DOE: dyspnea on exertion
Grade : Hugh Johns grade of exertional dyspnea
Table 2. Change in his symptoms and functions over time: 60, M, Ex, Eye, BHL, Lung 31 yrs,
While the therapeutic effects in these cases were by no means stellar, they did bring about
symptomatic relief, relatively good functional stabilization, and improved radiographic
findings. It remains unsolved whether antifibrotic drugs such as pirfenidone are effective for
fibrotic lesions in patients with sarcoidosis.
3.2. Treatment for cardiac sarcoidosis
Cardiac lesions can be patchily distributed in the four chambers of the heart. The dysfunctions
they cause range from arrhythmia to right bundle block, left bundle block, and complete
atrioventricular block leading to cardiac failure or cardiac arrest [23].
Sarcoidosis280
aAt the time of initial 
exam 27 years before
b
27 years after, revisited 
to the clinic
Figure 4. Longitudinal course of pulmonary fibrosis in patients with sarcoidosis: Plain chest radiograph 60-year-old
male, ex-smoker, chief complaints of cough and exertional dyspnea Eye, BHL, and lung (30-year duration) a : at the
initial exam in Kyoto University 27 years earlier b: at the revisit to the clinic 27 years later
a
7.30.2008
b 
3.3.2010
Figure 5. Longitudinal course of pulmonary fibrosis in patients with sarcoidosis: High-resolution CT findings 60-year-
old male, ex-smoker, chief complaints of cough and exertional dyspnea Eye, BHL, and lung (30-year duration) a : when
corticosteroids and methotrexate were introduced b: after 2 years of therapy
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The Japanese Society of Sarcoidosis and Other Granulomatous Disorders published revised
guidelines for the diagnosis of cardiac sarcoidosis [24]. These guidelines proposed criteria for
definite diagnosis and clinical diagnosis: 1) Definite group, histological diagnosis by cardiac
biopsy; 2) Clinical diagnosis group, negative biopsy with proven extracardiac sarcoidosis and
satisfaction of 1 of 4 major criteria and 2 or more minor criteria. The major criteria were
advanced AV block, basal thinning of the ventricular septum, positive cardiac gallium uptake,
and left ventricular ejection fraction of less than 50 %. The minor criteria were abnormal ECG
findings (ventricular tachycardia, multifocal frequent premature ventricular contractions,
complete right bundle branch block pathologic Q waves, or abnormal axis deviation, UCG
abnormality (regional wall motion abnormalities, ventricular aneurysm, or unexplained
increase in wall thickness), perfusion defects detected by myocardial scintigraphy, delayed
gadolinium enhancement of the myocardium on cardiac MRI scanning, and interstitial fibrosis
or monocyte infiltration greater than moderate grade by endomyocardial biopsy. As the
positive biopsy rate seems to be lower, the aforesaid guidelines are useful in a patients with
proven noncardiac sarcoidosis and suspected cardiac involvement [23].
Regarding treatment, published data on several uncontrolled series of patients with cardiac
sarcoidosis have suggested that steroids may be a valuable therapy for this condition. Yet no
randomized control data are available to support this. In a retrospective series of 48 cases of
cardiac sarcoidosis from Japan, high-dose steroid therapy seemed to be ineffective for patients
with a pretreatment left ventricular ejection fraction of less than 30%, whereas improvement
in ejection fraction and a decrease in left ventricular end-diastolic volume was seen in patients
with a pretreatment ejection fraction of between 30% and 55% [4]. In a retrospective study from
France, corticosteroid therapy improved abnormal echocardiographic parameters in 78% of
cases and symptoms completely resolved in 9 of 17 patients presenting with congestive heart
failure [25]. In a retrospective study of cardiac sarcoidosis in 30 Japanese patients who received
40 mg or more of prednisone daily and 45 patients who received less than 30 mg/d, there was
no apparent survival benefit of high-dose prednisone over the lower dose [13].
No data are available to support the efficacy of additional immunosuppressive therapy for
cardiac sarcoidosis with cyclophosphamide, methotrexate, or cyclosporine. Infliximab and
etanercept, agents used against rheumatoid arthritis via their actions against tumor necrosis
factor-α, have recently been proposed as treatments for some forms of chronic, refractory
sarcoidosis [26].
3.3. Methotrexate for the treatment of cardiac sarcoidosis
This chapter presents the findings of a small open label comparative study by our group.
Long-term functional changes of ejection fraction on echocardiography were compared
between patients who received combination therapy (low-dose prednisolone and methotrex‐
ate) and patients who received corticosteroids only.
As shown in table 3, there were no significant differences in sex distribution, duration of
sarcoidosis, the number of lesions, or the frequency of pace maker implantation, though the
age at the time of drug introduction tended to be higher in the patients treated with cortico‐
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steroids. There were no significant differences in the number of lesion sites, except for the
number renal stones (higher in patients on corticosteroids). There were no significant differ‐
ences in abnormal findings on electrocardiogram between the two groups (Table 4). Guided
by these findings, we followed the ejection fraction (%) at one-year intervals after the intro‐
duction of the therapy. As shown in Table 5, ejection fraction stabilized in the combination
therapy group 3 to 5 years after the first treatment.
CS only CS+MTX p-value
Af 0 1
PVC 1 0.463
CRBB 0 2
LBBB 6 7
CAVB
basal thinning 7 9 0.101
Af:atrial fibrilation, PVC: premature ventricular contractions
CRBBB : complete right bundle branch block, LBBB: left bundle branchblock
CAVB: complete atrioventricular block
Basal thinning: basal thinning of the ventricular septum
p-value: less than 0.05 as statistically significant
Table 4. Comparison of the electrocardiographic abnormalities between the steroid treated and the combination
therapy
CS only CS+MTX p-value
No of the cases 7 13
Age (years) 67±12.5* 56.5±13.7 0.07
M:W 2:05 5:08 0.66
duration (mos) 92.1±70.4 64.7±41.0 0.63
No of the extracardiac lesion 3.86±1.26 3.85±1.52 0.83
pace maker 6 11 0.95
CS:corticosteroid, MTX: methotrexate
M:man, W:woman, duration: from the detection to the introduction of the therapy,
* Figures express mean±standard deviation (SD)
p-value: less than 0.05 as statistically significant
Table 3. Clinical profiles in patients studied
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EF % CS only CS+MTX p-value
0* 56.1±13.1 58.4±15.3 0.812
12 48.0±16.7 55.5±15.3 0.383
36 41.2±9.8 58.6±11.6 0.007
60 41.0±13.1 56.2±12.3 0.069
96 48.7±9.2 55.0±25.2
EF : ejection fraction (%) on echocardiography
CS: corticosteroid, MTX: methotrexate
* months from the intorduction of the treatment
Figures express mean±standard deviation (SD)
p-value: less than 0.05 as statistically significant
Table 5. Comparison of the ejection fraction on echocardiography between the steroid treated and the combination
therapy
In the corticosteroid group, cardiac enlargement was found on plain chest radiographs at 3 to
5 years after the commencement of therapy in association with a decrease in ejection fraction
(see, for example, Figs. 6 and 7). Meanwhile, combination therapy restored or stabilized the
ejection fraction and cardiac enlargement on chest radiograph (see, for example, Figs. 8 and 9).
EF (%)
0
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1 2 3 4 5 6 7 8 9 10
months
EF
 (%
)
EF (%)
EF %
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0 12 36 48 60 8472
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24
Figure 6. Longitudinal course of the ejection fraction on UCG 74-year-old female, nonsmoker, eye, renal stone, BHL,
ACE 28.3, heart with complete AV block Ordinate: ejection fraction (%) on echocardiography Abscissa: months from
the introduction of therapy
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a b c
Figure 7. Longitudinal course of plain chest radiograph 74-year-old female, nonsmoker, eye, renal stone, BHL, ACE
28.3, heart with complete AV block a: when the corticosteroid therapy was introduced, b: after 5 years of treatment, c:
after 7 years of treatment
EF %
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Figure 8. Longitudinal course of the ejection fraction on UCG 62-year-old female, nonsmoker, BHL, lung, ACE 29.0,
heart with complete AV block Ordinate: ejection fraction (%) on echocardiography Abscissa: months from the intro‐
duction of therapy
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a b c
Figure 9. Longitudinal course of plain chest radiograph 62-year-old female, nonsmoker, BHL, lung, ACE 29.0, heart
with complete AV block, a: when the introduction of corticosteroid and methotrexate therapy was introduced, b: after
2 years of treatment c: after 5 years of treatment
Eight patients received methotrexate in our clinic after treatment with corticosteroid therapy
in another hospital. Some presented with decreased ejection fraction suggestive of congestive
heart failure when they came to our clinic. Yet even for those patients, the add-on methotrexate
improved the ejection fraction over a period years.
During long-term treatment with methotrexate and low-dose of prednisolone, there were no
serious adverse effects such as bone marrow suppression, opportunistic infection, or drug-
related pneumonia in our series.
At present we propose the following therapeutic strategy: in patients with cardiac sarcoidosis
(especially those with pace makers because of complete AV block), a combination therapy of
low-dose prednisolone and methotrexate as the initial treatment following long-term mainte‐
nance therapy will stabilize cardiac function with few adverse effects. A large-scale controlled
prospective study to assess this approach will of course be warranted.
4. Conclusion
It is important to evaluate the whole clinical course in patients with sarcoidosis. Therapeutic
decisions should be based on the clinical course, especially for chronic patients who need long-
term treatment. As our studies on patients with cardiac lesions and patients with fibrotic
pulmonary lesions demonstrate, weekly methotrexate therapy with or without small doses of
corticosteroids may stabilize the deterioration without eliciting adverse effects during long-
term treatment.
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Nomenclature
WASOG: World Association of Sarcoidosis and Other Granulomatous Disorders
ACCESS: A Case Control Etiologic Study of Sarcoidosis
ACE: Angiotensin converting enzyme
1,25-(OH)2 vitamin D: 1,25-dihydroxy- vitamin D
HRCT: High Resolution Computed Tomography
DLCO: diffusion capacity for carbon monoxide
AV block: atrioventricular block
ECG: Electrocardiography
UCG: ultrasound cardiography
FVC: forced vital capacity, FEV1: forced expiratory volume one second,
EF: ejection fraction, Reg.: regurgitation, sPAP : systolic pulmonary artery pressure
DOE: dyspnea on exertion
Grade : Hugh Johns grade of exertional dyspnea
CS:corticosteroid, MTX: methotrexate
M:man, W:woman
Af:atrial fibrilation, PVC: premature ventricular contractions
CRBBB : complete right bundle branch block, LBBB: left bundle branchblock
CAVB: complete atrioventricular block
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